Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Navega Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Navega Therapeutics

    Menu

    Navega Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Navega Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

              Details:

              The collaboration aims to support Navega's NT-Z001, which is being evaluated in the IND enabling stage for the treatment of chronic pain associated with rare diseases such as small fiber neuropathy and primary erythromelalgia.

              Lead Product(s): NT-Z001

              Therapeutic Area: Neurology Product Name: NT-Z001

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Recipient: Charles River Laboratories, Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY